|
|
|
11-50 employees
View all
|
|
Pharmaceuticals
|
|
Sussex Innovation Centre, Science Park square, Brighton, GB
|
|
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the company, please visit www.destinypharma.com
|
Destiny Pharma Plc Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Destiny Pharma Plc email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Destiny Pharma Plc customer service number in your country click here to find.
Kirsty Richardson is the CEO of Destiny Pharma Plc. To contact Kirsty Richardson email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.